Andras Horvath

USPTO Granted Patents = 17 (Patent Applications = 2)

CIPO Patents = 3

EPO Patents = 10 (Patent Applications = 4)

Average Co-Inventor Count = 4.1

ph-index = 2

Forward Citations = 12(Granted Patents)

Company Filing History:

6 out of 2,076

Janssen Pharmaceutica Nv

patents

4 out of 159

Janssen Pharmaceuticals, Inc.

patents

3 out of 34

Aragon Pharmaceuticals, Inc.

Alios Biopharma, Inc.

patents

6. 1 out of 66

Tibotec Pharmaceuticals Ltd.

patents

Years Active: 2012-2025

Loading Chart...

17 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12459948 - Processes and intermediates for preparing a Btk inhibitor (2025-11-04),

2. 12215110 - Processes and intermediates for preparing a Btk inhibitor (2025-02-04),

3. 11040953 - Process for the preparation of a diarylthiohydantoin compound (2021-06-22),

4. 10723714 - Processes for the preparation of a diarylthiohydantoin compound (2020-07-28),

5. 10316015 - Processes for the preparation of a diarylthiohydantoin compound (2019-06-11),

6. 10183945 - Method of preparing AZA-pyridone compounds (2019-01-22),

7. 9688655 - Process for the preparation of a diarylthiohydantoin compound (2017-06-27),

8. 9586893 - Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV (2017-03-07),

9. 9328108 - Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435 (2016-05-03),

10. 9227965 - Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV (2016-01-05),

11. 9115077 - Processes and intermediates for preparing a macrocyclic protease inhibitor of hcv (2015-08-25),

12. 8981082 - Process for preparing an intermediate of the macrocyclic protease inhibitor TMC 435 (2015-03-17),

13. 8927722 - Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV (2015-01-06),

14. 8722892 - Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV (2014-05-13),

15. 8212043 - Processes and intermediates for preparing a macrocyclic protease inhibitor of HCV (2012-07-03),

Title: Andras Horvath: A Visionary in Technology and Sustainability

Introduction:

Andras Horvath, a distinguished inventor based in Turnhout, BE, is renowned for his relentless pursuit of innovation and unwavering commitment to sustainability. With a total of 15 patents to his name, Horvath continues to push boundaries and inspire a greener and more efficient future through his groundbreaking inventions.

Latest Patents:

Among his latest patents is the "Process for the preparation of a diarylthiohydantoin compound," which reveals innovative processes and intermediates for the preparation of Compound (X). This cutting-edge discovery is currently under investigation for its potential in the treatment of prostate cancer, showcasing Horvath's dedication to addressing critical health challenges through technology.

Career Highlights:

Throughout his career, Andras Horvath has made significant contributions to leading companies in the pharmaceutical and biotech industries. Notable among these are his roles at Janssen Pharmaceutica NV and Aragon Pharmaceuticals, Inc., where he spearheaded pioneering research initiatives that have shaped the landscape of healthcare innovation.

Collaborations:

Horvath's collaborative spirit has been instrumental in driving forward technological advancements. Working alongside esteemed colleagues such as Dominic Ormerod and Cyril Ben Haim, he has fostered a culture of innovation and excellence, leading to the development of groundbreaking solutions that have the potential to transform industries and improve lives.

Conclusion:

In conclusion, Andras Horvath's visionary approach to technology, coupled with his deep-rooted commitment to sustainability, positions him as a trailblazer in the world of invention. His inventive spirit and dedication to creating a better future serve as a testament to his remarkable legacy, inspiring generations to come in the pursuit of innovation for the betterment of society.

This text is generated by artificial intelligence and may not be accurate.